Bristol-Myers Squibb BMY Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
Based on trailing twelve months.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's return on assets?
- Bristol-Myers Squibb (BMY) reported return on assets of 8.1% in Q1 2026.
- How has Bristol-Myers Squibb's return on assets changed year-over-year?
- Bristol-Myers Squibb's return on assets increased by 45.6% year-over-year, from 5.6% to 8.1%.
- What is the long-term trend for Bristol-Myers Squibb's return on assets?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's return on assets has grown at a 33.4% compound annual growth rate (CAGR), from -7.8% to 24.8%.
- What does return on assets mean?
- How much profit the company squeezes out of everything it owns.
- How do you interpret return on assets?
- Higher means more productive assets. Unlike ROE, it is unaffected by leverage, so a wide ROE-minus-ROA gap flags a heavily levered balance sheet.
- How does return on assets compare across companies?
- Best compared within an industry — asset intensity varies enormously across sectors. Not meaningful for banks, whose assets are largely financial.